Evaluation of physiologically based pharmacokinetic models in risk assessment: An example with perchloroethylene

Critical Reviews in Toxicology

Volumn 35, Issue 5, 2005, Pages 413-433

  Clewell, Harvey J ^a,d   Gentry, P Robinan ^a   Kester, Janet E ^b   Andersen, Melvin E ^c  

^a ENVIRON Health Sciences Institute   (United States)

^b 602 E Georgia Avenue   (United States)

^c CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^d NONE   (United States)

Author keywords

PBPK Modeling; Perchloroethylene; Risk Assessment

Indexed keywords

TETRACHLOROETHYLENE; TRICHLOROACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOASSAY; BODY WEIGHT; CARCINOGENICITY; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; KIDNEY METABOLISM; LEUKEMIA; LIVER CELL CARCINOMA; LIVER METABOLISM; MALE; MATHEMATICAL MODEL; MONTE CARLO METHOD; MOUSE; NONHUMAN; NORMAL HUMAN; PROBABILITY; RAT; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TOXICOKINETICS; URINARY EXCRETION;

ANIMALS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; RISK ASSESSMENT; TETRACHLOROETHYLENE;

EID: 21844454441     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408440590931994     Document Type: Review

References (111)

1. Völkel, W., Friedewald, M., Lederer, E., Pähler, A., Parker, J., and Dekant, W. (1998). Biotransformation of perchloroethene: Dose-dependent excretion of trichloroacetic acid, dichloroacetic acid, and N-acetyl-S- (trichlorovinyl)-L-cysteine in rats and humans after inhalation. Toxicol. Appl. Pharmacol. 153(1):20-27.
2. Gearhart, J.M., Mahle, D.A., Greene, R.J., Seckel, C.S., Flemming, C.D., Fisher, J.W., and Clewell, H.J. (1993). Variability of physiologically-based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE). Toxicol. Lett. 68:131-144.
3. U.S. Environmental Protection Agency, (1994). Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. Washington, D.C: U.S. EPA. EPA/600/8-90/066F.
4. U.S. Environmental Protection Agency. (2003). Draft final guidelines for carcinogen risk assessment. Washington, D.C: U.S. EPA. EPA/630/P-03/001A.
5. Andersen, M.E., Boorman, G.A., Brusick, D.J., Cohen, S.M., Dragan, Y.P., Frederick, C.B., Goodman, J.I., Hard, G.C., Meek, B., O'Flaherty, E.J., and Robinson, D.E. (2000). Lessons learned applying the USEPA's proposed cancer guidelines to specific compounds. Toxicol. Sci. 53:159-172.
6. Clewell, H.J., and Andersen, M.E. (1985). Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health 1(4):111-131.
7. Clewell, H.J., Andersen, M.E., and Barton, H.A. (2002). A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environ. Health Perspect. 110(1):85-93.
8. Clewell, H.J. (1995). The application of physiologically-based pharmacokinetic modeling in human health risk assessment of hazardous substances. Toxicol. Lett. 79:207-217.
9. Andersen, M.E., Clewell, H.J., Gargas, M.L., Smith, F.A., and Reitz, R.H. (1987). Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87(2):185-205.
10. Clewell, H.J. (1995). Incorporating biological information in quantitative risk assessment: An example with methylene chloride. Toxicology 102:83-94.
11. Andersen, M., Sarangapani, R., Gentry, R., Clewell, H., Covington, T., and Frederick, C.B. (2000). Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: An example with acrylic acid. Toxicol. Sci. 57:312-325.
12. Frederick, C.B., Lomax, L.G., Black, K.A., Finch, L., Scribner, H., Kimbell, J., Morgan, K.T., Subramaniam, R.P., and Morris, J.B. (2002). Use of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry comparisons of ester vapors. Toxicol. Appl. Pharmacol. 183:23-40.
13. Andersen, M.E., Clewell, H.J., and Frederick, C.B. (1995). Applying simulation modeling to problems in toxicology and risk assessment - A short perspective. Toxicol. Appl. Pharmacol. 133(2):181-187.
14. Clewell, H.J., Gentry, P.R., Gearhart, J.M., Allen, B.C., and Andersen, M.E. (2001). Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci. Total Environ. 274:37-66.
15. Clewell, H.J., Lee, T.S., and Carpenter, R.L. (1994). Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: Methylene chloride. Risk Anal. 14(4):521-531.
16. Clewell, H.J. (1995). The use of physiologically based pharmacokinetic modeling in risk assessment: A case study with methylene chloride. In Low-Dose Extrapolation of Cancer Risks: Issues and Perspectives, eds. S. Olin et al., pp. 199-222. Washington, DC: ILSI Press.
17. Fisher, J.W., and Allen, B.C. (1993). Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models. Risk Anal. 13(1):87-95.
18. Clewell, H.J., Gentry, P.R., Covington, T.R., and Gearhart, J.M. (2000). Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 108(suppl. 2):283-305.
19. Fisher, J.W. (2000). Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. Environ. Health Perspect. 108:265-273.
20. Simmons, J.E., Boyes, W.K., Bushnell, P.J., Raymer, J.H., Limsakun, T., McDonald, A., Sey, Y.M., and Evans, M.V. (2002). A physiologically based pharmacokinetic model for trichloroethylene in the male Long-Evans rat. Toxicol. Sci. 69(1):3-15.
21. Chen, C.W., and Blancato, J.N. (1987). Role of pharmacokinetic modeling in risk assessment: Perchloroethylene as an example. In Pharmacokinetics in Risk Assessment. Drinking Water and Health, Vol. 8, pp. 369-390. Washington, DC: National Academy Press.
22. Ward, R.C., Travis, C.C., Hetrick, D.M., Andersen, M.E., and Gargas, M.L. (1988). Pharmacokinetics of tetrachloroethylene. Toxicol. Appl. Pharmacol. 93(1):108-117.
23. Bois, F.Y., Gelman, A., Jiang, J., Maszle, D.R., Zeise, L., and Alexeef, G. (1996). Population toxicokinetics of tetrachloroethylene. Arch. Toxicol. 70(6):347.
24. Bois, F.Y., Zeise, L., and Tozer, T.N. (1999). Precision and sensitivity of pharmacokinetic models for cancer risk assessment: Tetrachloroethylene in mice, rats, and humans. Toxicol. Appl. Pharmacol. 102(2):300-315.
25. Dallas, C.E., Chen, X.M., Muralidhara, S., Varkonyi, P., Tackett, R.L., and Bruckner, J.V. (1994). Use of tissue disposition data from rats and dogs to determine species-differences in input parameters for a physiological model for perchloroethylene. Environ. Res. 67(1):54-67.
26. Dallas, C.E., Chen, X.M., Obarr, K., Muralidhara, S., Varkonyi, P., and Bruckner, J.V. (1994). Development of a physiologically-based pharmacokinetic model for perchloroethylene using tissue concentration-time data. Toxicol. Appl. Pharmacol. 128(1):50-59.
27. Dallas, C.E., Muralidhara, S., Chen, X.M., Ramanathan, R., Varkonyi, P., Gallo, J.M., and Bruckner, J.V. (1994). Use of a physiologically-based model to predict systemic uptake and respiratory elimination of perchloroethylene. Toxicol. Appl. Pharmacol. 128(1):60-68.
28. Dallas, C.E., Chen, X.M., Muralidhara, S., Varkonyi, P., Tackett, R.L., and Bruckner, J.V. (1995). Physiologically based pharmacokinetic model useful in prediction of the influence of species, dose, and exposure route on perchloroethylene pharmacokinetics. J. Toxicol. Environ. Health 44(3):301-317.
29. Reitz, R., Gargas, M., Mendrala, A., and Schumann, A. (1996). In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokineticmodeling in rats, mice, and humans. Toxicol. Appl. Pharmacol. 136:289-306.
30. Loizou, G.D. (2001). The application of physiologically based pharmacokinetic modelling in the analysis of occupational exposure to perchloroethylene. Toxicol. Lett. 124(1-3):59-69.
31. Hattis, D., White, P., and Koch, P. (1993). Uncertainties in pharmacokinetic modeling for perchloroethylene: II. Comparison of model predictions with data for a variety of different parameters. Risk Anal. 13:599-610.
32. Hattis, D., White, P., Marmorstein, L., and Koch, P. (1990). Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors. Risk Anal. 10:449-458.
33. U.S. Environmental Protection Agency (1986). Addendum to the health assessment document for tetrachloroethylene (perchloroethylene). Updated carcinogenicity assessment for tetrachloroethylene (perchloroethylene). Washington, DC: EPA/600/8-82-005FA.
34. Office of Environmental Health Hazard Assessment. (2001). Public Health Coal for Tetrachloroethylene in Drinking Water. Oakland, CA: OEHHA.
35. Farrar, D., Allen, B., Crump, K., and Shipp, A. (1989). Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. Toxicol. Lett. 49:371-385.
36. U.S. Environmental Protection Agency. (2002). Risk assessment issue paper for: Carcinogenicity information for tetrachloroethylene (perchloroethylene, PERC) (CASRN 127-18-4). Cincinnati, OH: U.S. ETA.
37. Office of Environmental Health Hazard Assessment. (2003). Process for PHG development and chemicals undergoing evaluation. www.oehha.ca.gov/water/phg/ howphgs.html.
38. Smith, E.M., Miller, E.R., Woolson, R.F., and Brown, C.K. (1985). Bladder cancer risk among laundry workers, dry-cleaners and other chemically-related occupations. J. Occup. Med. 27(4):295-297.
39. Brown, D.P., and Kaplan, S.D. (1987). Retrospective cohort mortality study of dry cleaner workers using perchloroethylene. J. Occup. Med. 29:535-541.
40. Blair, A., Stewart, P.A., Tolbert, P.E., D, G., X, M.F., J, V., and Rayner, J. (1990). Cancer and other causes of death among a cohort of dry cleaners. Br. J. Ind. Med. 47(3):162-168.
41. Spirtas, R., Stewart, P.A., Lee, J.S., Marano, D.E., Forbes, C.D., Grauman, D.J., Pettigrew, H.M., Blair, A., Hoover, R.N., and Cohen, J.L. (1991). Retrospective cohort mortality study of workers at an aircraft maintenance facility. I. Epidemiological results. Br. J. Ind. Med. 48(8):515-530.
42. Aschengrau, A., Ozonoff, D., Paulu, C., Coogan, P., Vezina, R., Heeren, T., and Zhang, Y. (1993). Cancer risk and tetrachloroethylene-contaminated drinking water in Massachusetts. Arch. Environ. Health 48(5):284-292.
43. Cohn, P., Klotz, J., Bove, F., Berkowitz, M., and Fagliano, J. (1994). Drinking water contamination and the incidence of leukemia and non-Hodgkin's lymphoma. Environ. Health Perspect. 102:556-561.
44. Heineman, E.F., Cocco, P., Gomez, M.R., Dosemeci, M., Stewart, P.A., Hayes, R.B., Zahm, S.H., Thomas, T.L., and Blair, A. (1994). Occupational exposure to chlorinated aliphatic hydrocarbons and risk of astrocytic brain cancer. Am. J. Ind. Med. 26(2):155-169.
45. Ruder, A.M., Ward, E.M., and Brown, C.K. (2001). Mortality in dry-cleaning workers: An update. Am. J. Ind. Med. 39:121-132.
46. Ruder, A.M., Ward, E.M., and Brown, D.P. (1994). Cancer mortality in female and male dry-cleaning workers. J. Occup. Med. 36:867-874.
47. Anttila, A., Pukkala, E., Sallmen, M., Hernberg, S., and Hemminki, K. (1995). Cancer incidence among Finnish workers exposed to halogenated hydrocarbons. J. Occup. Environ. Med. 37:797-806.
48. Weiss, N.S. (1995). Cancer in relation to occupational exposure to perchloroethylene. Cancer Causes Control 6:257-266.
49. Agency for Toxic Substances and Disease Registry. (1997). Toxicological Profile for Tetrachloroethylene. www.atsdr.cdc.gov/toxprofiles/tp18.html
50. McLaughlin, J.K., and Blot, W.J. (1997). A critical review of epidemiology studies of trichloroethylene and perchloroethylene and risk of renal-cell cancer. Int. Arch. Occup. Environ. Health 70:222-231.
51. Mundt, K.A., Birk, T., and Burch, M.T. (2003). Critical review of the epidemiological literature on occupational exposure to perchloroethylene and cancer. Int. Arch. Occup. Environ. Health 76(7):473-491.
52. U.S. Environmental Protection Agency. (1985). Health assessment document for tetrachloroethylene (perchloroethylene). Washington, DC: U.S. EPA. EPA/600/3-82/005F.
53. National Cancer Institute. (1977). Bioassay of tetrachloroethylene for possible carcinogenicity CAS No. 127-18-4. Bethesda, MD: NCI.
54. National Toxicology Program. (1986). Toxicology and carcinogenesis studies of tetrachloroethylene (perchloroethylene) (CAS No. 127-18-4) in F344/N rats and B6C3FI mice (inhalation studies). Bethesda, MD: NIH. NIH Publication 86-2567.
55. U.S. Environmental Protection Agency. (1988). EPA staff comments on issues regarding the carcinogenicity of perchloroethylene (PERC) raised by the SAB. Washington, DC: U.S. EPA. EPA-SAB-EHC-88-011.
56. Caldwell, D.J. (1999). Review of mononuclear cell leukemia in F-344 rat bioassays and its significance to human cancer risk: A case study using alkyl phthalates. Regul. Toxicol. Pharmacol. 30:45-53.
57. 49
58. Buben, J., and O'Flaherty, E. (1985). Delineation of the role of metabolism in the hepatotoxicity of trichloroethylene and perchloroethylene: A dose-effect study. Toxicol. Appl. Pharmacol. 78:105-122.
59. Bolanowska, W., and Golacka, J. (1992). Absorption and elimination of tetrachloroethylene in humans under experimental conditions. Medycyna. Pracy. 23(2):109-119.
60. Vamvakas, S., Dekant, W., and Henschler, D. (1993). Nephrocarcinogenicity of haloalkenes and alkynes. In Renal Disposition and Nephrotoxicity of Xenobiotics, eds. M.W. Anders et al., pp. 323-342. San Diego, CA: Academic Press.
61. Ohtsuki, T., Sato, K., Koizumi, A., Kumai, M., and Ikeda, M. (1983). Limited capacity of humans to metabolize tetrachloroethylene. Int. Arch. Occup. Environ. Health 51:381-390.
62. Seiji, K., Inoue, O., Jin, C., Liu, Y.T., Cai, S.X., Ohashi, M., Watanabe, T., Nakatsuka, H., Kawai, T., and Ikeda, M. (1989). Dose-excretion relationship in tetrachloroethylene-exposed workers and the effect of tetrachloroethylene co-exposure on trichloroethylene metabolism. Am. J. Ind. Med. 16(6):675-684.
63. Goldsworthy, T.L., and Popp, J.A. (1987). Chlorinated hydrocarbon-induced peroxisomal enzyme activity in relation to species and organ carcinogenicity. Toxicol. Appl. Pharmacol. 88:225-253.
64. Odum, J., Green, T., Foster, J.R., and Hext, P.M. (1988). The role of trichloroacetic acid and peroxisome proliferation in the differences in carcinogencity of perchloroethylene in the mouse and rat. Toxicol. Appl. Pharmacol. 92:103-112.
65. Maronpot, R.R., Anna, C.H., Devereux, T.R., Lucier, G.W., Butterworth, B.E., and Anderson, M.W. (1995). Considerations concerning the murine hepatocarcinogenicity of selected chlorinated hydrocarbons. Prog. Clin. Biol. Res. 391:305-323.
66. Dekant, W., Birner, G., Werner, M., and Parker, J. (1998). Glutathione conjugation of perchloroethene in subcellular fractions from rodent and human liver and kidney. Chem. Biol. Interact. 116:31-43.
67. Pahler, A., Parker, J., and Dekant, W. (1999). Dose-dependent protein adduct formation for kidney, liver, and blood of rats and in human blood after perchloroethene inhalation. Toxicol. Sci. 48(1):5-13.
68. Lash, L.H., and Parker, J.C. (2001). Hepatic and renal toxicities associated with perchloroethylene. Pharmacol. Rev. 53:177-208.
69. Dekant, W., Metzler, M., and Henschler, D. (1986). Identification of S-1,2,2-trichlorovinyl-N-acetylcysteine as a urinary metabolite of tetrachloroethylene: Bioactivation through glutathione conjugation as a possible explanation of its nephrocarcinogenicity. J. Biochem. Toxicol. 1(2):57-72.
70. Schumann, A.M., Quast, J.F., and Watanabe, P.G. (1980). The pharmacokinetics and macromolecular interactions of perchloroethylene in mice and rats as related to oncogenicity. Toxicol. Appl. Pharmacol. 55(2):207-219.
71. Birner, G., Richling, C., Henschler, D., Anders, M.W., and Dekant, W. (1994). Metabolism of tetrachloroethene in rats: Identification of N′-(dichloroacetyl-L-lysine and N′-(trichloroacetyl)-L-lysine as protein adducts. Chem. Res. Toxicol. 7:724-732.
72. Pahler, A., Birner, G., Parker, J., and Dekant, W. (1998). Generation of antibodies to di- and trichloroacetylated proteins and immunochemical detection of protein adducts in rats treated with perchloroethene. Chem. Res. Toxicol. 11:995-1004.
73. Green, S.M., Khan, M.F., Kaphalia, B.S., and Ansari, G.A.S. (2001). Immunohistochemical localization of trichloroacylated protein adducts in tetrachloroethene-treated mice. J. Toxicol. Environ. Health A 63:145-157.
74. Ebrahim, A.S., Babakrishnan, K., and Sakthisekaran, D. (1996). Perchloroethylene-induced alterations in glucose metabolism and their preventionby deoxy-D-glucose and vitamin E in mice. J. Appl. Toxicol. 16:339-348.
75. Ebrahim, A.S., Babu, E., Thirunavikkarasu, C., and Sakthisekaran, D. (2001). Protective role of vitamin E, 2-deoxy-D-glucose, and taurine on perchloroethylene induced alterations in ATPases. Drug Chem. Toxicol. 24:429-437.
76. Toraason, M., Clark, J., Dankovic, D., Mathias, P., Skaggs, S., Walker, C., and Werren, D. (1999). Oxidative stress and DNA damage in Fischer rats following acute exposure to trichloroethylene or perchloroethylene. Toxicology 138:43-53.
77. Toraason, M., Butler, M.A., Ruder, A., Forrester, C., Taylor, L., Ashley, D.L., Mathias, P., Marlow, K.L., Cheever, K.L., Krieg, E., and Wey, H. (2003). Effect of perchloroethylene, smoking, and race on oxidative DNA damage in female dry cleaners. Mutat. Res. 539:9-18.
78. Austin, E.W., Okita, J.R., Okita, R.T., Larson, J.L., and Bull, R.J. (1995). Modification of lipoperoxidative effects of dichloroacetate and trichloroacetate is associated with peroxisome proliferation. Toxicology: 97(1-3):59-69.
79. Walgren, J.E., Kurtz, D.T., and McMillan, J.M. (2000). The effect of the trichloroethylene metabolites trichloroacetate and dichloroacetate on peroxisome proliferation and DNA synthesis in culture human hepatocytes. Cell Biol. Toxicol. 16:257-273.
80. Savas, U., Hsu, M.-H., and Johnson, E.F. (2003). Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Arch. Biochem. Biophys. 409:212-220.
81. Chinetti, G., Fruchart, J.C., and Staels, B. (2000). Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49(10):497-505.
82. Delerive, P., Fruchart, J.C., and Staels, B. (2001). Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 169(3):453-459.
83. Blanquart, C., Barbier, O., Fruchart, J.C., Staels, B., and Clineur, C. (2003). Peroxisome proliferator-activated receptors: Regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 85(2-5):267-273.
84. Green, T., Odum, J., Nash, J., and Foster, J. (1990). Perchloroethylene-induced rat kidney tumors: An investigation of the mechanisms involved and their relevance to humans. Toxicol. Appl. Pharmacol. 103:77-89.
85. Green, T., and Odom, J. (1985). Structure/activity studies of the nephrotoxic and mutagenic action of cysteine conjugates of chloro- and fluoroalkenes. Chem. Biol. Interact. 54:15-31.
86. Vamvakas, S., Dekant, W., Berthold, K., Schmidt, S., Wild, D., and Henschler, D. (1987). Enzymatic transformation of mercapturic acids derived from halogenated alkenes to reactive and mutagenicintermediates. Biochem. Pharmacol. 36:2741-2748.
87. Ramsey, J., and Andersen, M. (1984). A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73:159-175.
88. Barton, H.A., and Clewell, H.J. (2000). Evaluating noncancer effects of trichloroethylene: Dosimetry, mode of action, and risk assessment. Environ. Health. Perspect. 108:323-334.
89. U.S. Environmental Protection Agency. (1988). Reference physiological parameters in pharmacokinetic Modeling. Washington, DC: U.S. EPA. EPA/600/6-88/004.
90. Gargas, M.L., Burgess, R.J., Voisard, D.E., Cason, G.H., and Andersen, M.E. (1989). Partition coefficients of low molecular weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 98:87-99.
91. Pegg, D.G., Zempel, J.A., Braun, W.H., and Watanabe, P.G. (2002). Disposition of tetrachloro(14C)ethylene following oral and inhalation exposure in rats. Toxicol. Appl. Pharmacol. 51:465-474.
92. Albanese, R.A., Banks, H.T., Evans, M.V., and Potter, L.K. (2002). Physiologically based pharmacokinetic models for the transport of trichloroethylene in adipose tissue. Bull. Math. Biol. 64(1):97-131.
93. Fernandez, J., Guberan, E., and Caperos, J. (1976). Experimental human exposures to tetrachloroethylene vapor and elimination in breath after inhalation. Am. Ind. Hyg. Assoc. J., 37:143-150.
94. Monster, A., Boersma, G., and Steenweg, H. (1979). Kinetics of tetrachloroethylene in volunteers; influence of exposure concentration and work load. Int. Arch. Occup. Environ. Health 42:303-309.
95. Ikeda, M., Otsuji, H., Imamura, T., and Komoike, Y. (1972). Urinary excretion of total trichloro-compounds, trichloroethanol, and trichloroacetic acid as a measure of exposure to trichloroethylene and tetrachloroethylene. Br. J. Ind. Med. 29(3):328-333.
96. Stewart, R.D., Baretta, E.D., Dodd, H.C., and Torkelson, T.R. (1970). Experimental human exposure to tetrachloroethylene. Arch. Environ. Health 20:224-229.
97. Stewart, R., and Dodd, H. (1964). Absorption of carbon tetrachloride, trichloroethylene, tetrachloroethylene, methylene chloride, and 1,1,1-trichloroethane through the human skin. Am. Ind. Hyg. Assoc. J. 25:439-446.
98. Mitoma, C., Steeger, T., Jackson, S.E., Wheeler, K.P., Rogers, J.H., and Milman, H.A. (1985). Metabolic disposition study of chlorinated hydrocarbons in rats and mice. Drug Chem. Toxicol. 8:183-194.
99. Frantz, S., and Watanabe, P. (1983). Tetrachloroethylene: Balance and tissue distribution in male Sprague-Dawley rats by drinking-water. Toxicol. Appl. Pharmacol. 69:66-72.
100. Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R., and Beliles, R.P. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13(4):407-484.
101. Astrand, P., and Rodahl, K. (1970). Textbook of work physiology. New York: McGraw-Hill.
102. Hanioka, N., Jinno, H., Takahashi, A., Nakano, K., Yoda, R., Nishimura, T., and Ando, M. (1995). Interaction of tetrachloroethylene with rat hepatic microsomal P-450 dependent monooxygenases. Xenobiotica 25:151-165.
103. Costa, A.K., and Ivanetich, K.M. (1980). Tetrachloroethylene metabolism by the hepatic microsomal cytochrome P-450 system. Biochem. Pharmacol. 29:2863-2869.
104. Lumpkin, M.H., Bruckner, J.V., Campbell, J.L., Dallas, C.E., White, C.A., and Fisher, J.W. (2003). Plasma binding of trichloroacetic acid in mice, rats, and humans under cancer bioassay and environmental exposure conditions. Drug. Metab. Dispos. 31:1203-1207.
105. Dankovic, D., and Bailer, J. (1994). The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model. Fundam. Appl. Toxicol. 22:20-25.
106. Kharasch, E.D., Hankins, D.C., and Thummel, K.E. (1995). Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 82(3):689-699.
107. U.S. Environmental Protection Agency. (1986). Guidelines for carcinogen risk assessment. Fed. Reg. 51:33992.
108. U.S. Environmental Protection Agency. (2003). Guidelines for carcinogen risk assessment. Washington, DC: U.S. EPA. NCEA-F-0644.
109. U.S. Environmental Protection Agency. (1992). Request for comments on draft report on cross-species scaling factor for cancer risk assessment. Fed. Reg. 57:24152-24173.
110. Clewell, H.J. III, and Andersen, M.E. (2004). Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: An example with trichloroethylene. Crit. Rev. Toxicol. 34(5):385-445.
111. Templin, M.V., Stevens, D.K., Stenner, R.D., Bonate, P.L., Tuman, D., and Bull, R.J. (1995). Factors affecting species differences in the kinetics of metabolites of trichloroethylene. J. Toxicol. Environ. Health 44:435-447.